[144] Disc Medicine, Inc. SEC Filing

Rhea-AI Filing Summary

Form 144 filed for Disc Medicine, Inc. (IRON) reports a proposed sale of 2,287 shares of Common Stock through Merrill Lynch, with an aggregate market value of $136,648.25 and an approximate sale date of 08/22/2025 on Nasdaq. The shares were acquired in a private placement from the issuer on 05/01/2020 and paid in cash on that date. The filer reports no securities sold during the past three months for the account. The filing includes the standard representation that the seller is not aware of undisclosed material adverse information and references Rule 10b5-1 plan adoption language.

Insights

Securities Analyst

TL;DR: A small, scheduled insider sale of 2,287 shares (reported value $136,648.25) via Merrill Lynch; appears routine rather than market-moving.

The filing documents a proposed sale subject to Rule 144 procedures: the shares were acquired in a private placement on 05/01/2020 and are now being offered through a broker with an approximate sale date of 08/22/2025. The filer states there were no sales in the prior three months and provides the standard certification regarding material non-public information and 10b5-1 plan language. Based solely on the filing details, this disclosure describes a single, discrete transaction and does not present new operational or financial information about the issuer.

Corporate Governance Expert

TL;DR: Compliance-focused disclosure consistent with Rule 144; the form shows procedural adherence but no governance change.

The notice includes required data points: broker name (Merrill Lynch), class (Common Stock), quantity (2,287), aggregate market value ($136,648.25), shares outstanding reported (34,765,581), and acquisition details (private placement on 05/01/2020 paid in cash). The absence of sales in the prior three months and the signer’s statement about material information suggest the filer is following disclosure and insider-trading protocols. There is no indication of leadership change, related-party transaction beyond the private placement, or other governance actions in this filing.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	Merrill Lynch One Bryant Park New York NY 10036	2287	136648.25	34765581	08/22/2025	Nasdaq

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	05/01/2020	Private Placement	Issuer			2287	05/01/2020	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the Form 144 for Disc Medicine, Inc. (IRON) disclose?

The form discloses a proposed sale of 2,287 shares of Common Stock with an aggregate market value of $136,648.25, to be sold via Merrill Lynch on or about 08/22/2025 on Nasdaq.

When and how were the shares being sold acquired?

The shares were acquired in a private placement from the issuer on 05/01/2020, and payment was made in cash on that date.

Does the filing report any securities sold in the past three months for the seller?

The filing states "Nothing to Report" under securities sold during the past three months.

Which broker is handling the proposed sale and where will it trade?

The broker listed is Merrill Lynch, One Bryant Park, New York, and the filing lists the exchange as Nasdaq.

Does the Form 144 indicate any material non-public information or a 10b5-1 plan date?

The filing includes the standard representation that the seller does not know any material adverse information not publicly disclosed and references the procedure for indicating a Rule 10b5-1 plan adoption date, but no specific plan adoption date is provided in the form.